JPMorgan Chase & Co. reissued their neutral rating on shares of GlaxoSmithKline PLC (NYSE:GSK) in a research note released on Friday.

Analyst Recommendations for GlaxoSmithKline PLC (NYSE:GSK)

Several other analysts also recently issued reports on GSK. Zacks Investment Research upgraded GlaxoSmithKline PLC from a sell rating to a hold rating in a report on Monday, July 25th. Citigroup Inc. restated a buy rating on shares of GlaxoSmithKline PLC in a report on Wednesday, August 10th. BNP Paribas downgraded GlaxoSmithKline PLC from a neutral rating to an underperform rating in a report on Tuesday, September 13th. Beaufort Securities restated a buy rating on shares of GlaxoSmithKline PLC in a report on Tuesday, August 2nd. Finally, Jefferies Group upgraded GlaxoSmithKline PLC from a hold rating to a buy rating in a report on Thursday, July 14th. Two equities research analysts have rated the stock with a sell rating, eleven have assigned a hold rating, nine have assigned a buy rating and one has assigned a strong buy rating to the stock. The stock currently has an average rating of Hold and an average price target of $47.53.

GlaxoSmithKline PLC (NYSE:GSK) opened at 43.21 on Friday. The firm’s 50-day moving average is $43.84 and its 200-day moving average is $42.60. GlaxoSmithKline PLC has a 12 month low of $37.24 and a 12 month high of $45.58. The firm has a market capitalization of $105.02 billion, a PE ratio of 2700.62 and a beta of 0.85.

The company also recently announced a dividend, which will be paid on Thursday, October 13th. Investors of record on Friday, August 12th will be given a $0.494 dividend. The ex-dividend date is Wednesday, August 10th. GlaxoSmithKline PLC’s dividend payout ratio (DPR) is currently 6,600.00%.

Hedge funds and other institutional investors have recently modified their holdings of the company. FMR LLC boosted its position in shares of GlaxoSmithKline PLC by 29.8% in the second quarter. FMR LLC now owns 20,701,378 shares of the pharmaceutical company’s stock valued at $897,198,000 after buying an additional 4,757,238 shares during the period. Fisher Asset Management LLC boosted its position in shares of GlaxoSmithKline PLC by 0.6% in the second quarter. Fisher Asset Management LLC now owns 11,730,875 shares of the pharmaceutical company’s stock valued at $510,528,000 after buying an additional 73,020 shares during the period. State Street Corp boosted its position in shares of GlaxoSmithKline PLC by 1.1% in the second quarter. State Street Corp now owns 10,472,620 shares of the pharmaceutical company’s stock valued at $453,884,000 after buying an additional 111,349 shares during the period. Bank of New York Mellon Corp boosted its position in shares of GlaxoSmithKline PLC by 0.6% in the second quarter. Bank of New York Mellon Corp now owns 5,976,687 shares of the pharmaceutical company’s stock valued at $259,030,000 after buying an additional 35,788 shares during the period. Finally, Ameriprise Financial Inc. boosted its position in shares of GlaxoSmithKline PLC by 24.7% in the second quarter. Ameriprise Financial Inc. now owns 3,038,134 shares of the pharmaceutical company’s stock valued at $132,800,000 after buying an additional 602,693 shares during the period. 8.79% of the stock is owned by hedge funds and other institutional investors.

About GlaxoSmithKline PLC

GlaxoSmithKline plc (GSK) is a healthcare company. The Company is engaged in the creation and discovery, development, manufacture and marketing of pharmaceutical products, including vaccines, over-the-counter (OTC) medicines and health-related consumer products. The Company’s segments include Pharmaceuticals, Pharmaceuticals R&D, Vaccines and Consumer Healthcare.

5 Day Chart for NYSE:GSK

Receive News & Ratings for GlaxoSmithKline PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline PLC and related companies with Analyst Ratings Network's FREE daily email newsletter.